Equities

NANO MRNA Co Ltd

NANO MRNA Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.11
  • Today's Change-0.02 / -1.77%
  • Shares traded2.22k
  • 1 Year change-22.38%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year NANO MRNA Co Ltd had revenues fall -32.98% from 202.19m to 135.51m, though the company grew net income from a loss of 1.31bn to a smaller loss of 780.00m.
Gross margin78.30%
Net profit margin-848.97%
Operating margin-1,070.24%
Return on assets-12.33%
Return on equity-17.92%
Return on investment-13.57%
More ▼

Cash flow in JPYView more

In 2024, NANO MRNA Co Ltd increased its cash reserves by 20.29%, or 265.67m. Cash Flow from Investing totalled 793.01m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 585.08m for operations while cash generated from financing totalled 3.73m.
Cash flow per share-9.23
Price/Cash flow per share--
Book value per share46.27
Tangible book value per share46.27
More ▼

Balance sheet in JPYView more

NANO MRNA Co Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio9.24
Quick ratio9.24
Total debt/total equity0.3405
Total debt/total capital0.2540
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.